Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-02102-9. Published online 15 December 2022.

In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.